Top Back to top

RACE: A prospective Randomized multicenter study comparing horse Antithymocyte globuline (hATG) + Cyclosporine A (CsA) with or without Eltrombopag as front-line therapy for severe aplastic anemia patients

Study number:
8409032
Type of transplant:
 
Short title:
RACE
Study status:
 
Deadline for data collection:
 
Study design:
Open label randomised clinical trial
Primary objective:
To investigate whether Eltrombopag added to standard immunosuppressive treatment increases the rate of early (at three months) complete response in untreated AA patient.
Key inclusion criteria:
≥ 15 years, (very) severe aplastic anemia patients
Country:
France
Germany
Italy
Netherlands
Spain
Switzerland
United Kingdom
Principal investigator:
Antonio Risitano, Regis Peffault de Latour
Principal investigator email:
 
Study coordinator email:
RACEtrial@lumc.nl

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org